Regular follow-ups with clinical assessments, biomarker tracking, and protocol optimization to maximize your cosmetic and longevity outcomes
Lilly noted in a press release that at 80 weeks, all the doses of retatrutide met the primary and key secondary endpoints for obesity, delivering clinically meaningful weight loss. TRIUMPH-1 highlights the importance of options and the potential for retatrutide to help people across various stages of their obesity journey, Kenneth Custer, PhD, executive vice president and president, Lilly Cardiometabolic Health, said in a press release
Similar findings were noted in a study on its use for weight management (an off-label use) in those who were overweight or had obesity
Furthermore, GLP-1 weight loss medication is believed to influence metabolism in various ways, such as improving fat breakdown or reducing fat accumulation
What human evidence exists for this specific question, not just related biology